Emcure Pharmaceuticals has recently informed exchanges that the company signed a royalty-free licensing agreement with Gilead Sciences to manufacture and supply generic versions of lenacapavir for HIV prevention and treatment in 120 countries, especially in low- and lower-middle-income regions.
The partnership will ensure the availability of affordable lenacapavir and highlights Emcure’s dedication to innovative global healthcare.
Managing Director and CEO, Emcure Pharmaceuticals Ltd., stated, “We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide.”
